Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the refractive Technology Portfolio of Aboot medical optics
http://www.amo-inc.com/products
ARFR FDA approved products will fit perfectly with them
thanks, need to get some sleep. good luck in the morning!
BTW you've got a classy board here...not like to zoo i'm in! lol
it is never too late ;)looks very promising one ,it might gap ~
hi, is it too late to get in this awesome stock?
what do you think will be the opening pps?
thanks
longhorn2745
ARFR is subject to a BUYOUT by ABOTT that is expanding their vision care portfolio
from Abott
Abott to acquire Visiogen
http://abbott.com/global/url/pressRelease/en_US/60.5:5/Press_Release_0763.htm
ABOTT is positioning themselves as:
"The Complete Refractive Solution
It is our methodology for delivering the promise of Vision. For life.
We offer the widest range of proven refractive technologies for myopia, hyperopia, astigmatism, presbyopia, cataract, spherical aberration and corneal health. Our proven programs and systems help eye care professionals build their refractive practices. And our proven clinical and educational programs help eye care professionals master refractive technologies."
link:
http://www.amo-inc.com/
and Advanced Refractive Technologies is the perfect
candidat for Abott portfolio
about ARFR
Advanced Refractive Technologies is an ophthalmic developmental and marketing company, which is focusing upon the most important areas of need in ophthalmology.
The Company is developing both medical devices as well as pharmaceutical agents to be used in important pathologies within the ophthalmology market.
These areas include:
*
Cataract detection
*
Cataract surgery
*
Glaucoma therapy
*
Age-Related Macular degeneration
Advanced Refractive Technologies is now preparing to revolutionize the ophthalmic market
http://www.advancedrefractive.com/Company.htm
yesterday volume was record volume something is occuring here
ARFR Accupulse Cataract Emulsifier mentionned in recent report:
The Future of Ophthalmic Devices, Market Forecasts and Growth Opportunities to 2016 - The Vision Care Segment Emerges as a Key Revenue Generator - a new market research
http://www.live-pr.com/en/the-future-of-ophthalmic-devices-market-r1048442429.htm
we can see ARFR technology listed
under :
7.2 Cataract Surgery Devices 69
7.2.1 Advanced Refractive Technologies: Accupulse Cataract Emulsifier 70
Congrats! It's well-deserved and the board is lucky to have you as mod!
Last filing 2007 for 2006
will they catch up
was trading this a few years ago
then they lost their agreement w a german co
and nothing since
thx
MK
cheers, mate!
you have my vote for mod!
ARFR STRONG CLOSE UP 100%
Tomorrow we easily break through weak resistance .0017
THEN IT IS
!!!!!!!!!!BLUE SKY BREAKOUT!!!!!!!!!!!!!!!!
look forward to it. I was planning on cutting my losses in this but now I'm instead thinking about dumping some other losers and adding more thanks to your dd.
great :) more DD are coming tonight :)
nice! I just added some .0016s.
i am applying to mod position here ,i like this one a lot~
their technology is in LASIK surgery procedure used worldwide!! ~
Sounds like a stock to hold for a while. Nice work!
HUGE Management on board check this :
Dr. Richard Keates – Chairman of the Board
Dr. Keates is a well-respected ophthalmologist, consultant, and professor. He has served on various boards including Frigitronics (NYSE), Med Chem (NYSE), Autonomous Technologies (NASDAQ) and Chiron Vision. Dr. Keates has consulted for leading health care companies including Chiron Vision, IOLAB, Alcon, and Bausch & Lomb. He has published over 100 articles in Ophthalmology. Among his many faculty appointments, Dr. Keates has been a professor at Ohio State University, Professor and Chairman of the Ophthalmology Department at the University of California, Irvine, and currently is a Professor at New York Medical College. Dr. Keates is the past President of the New York Intraocular Lens Society and past President of the New York Keratorefractive Society. Dr. Keates graduated from the University of Pennsylvania and from the Jefferson Medical College. He completed his Ophthalmology training at Harvard Basic Sciences in Ophthalmology and The Manhattan Eye, Ear & Throat Hospital
Randal Bailey – CEO and President
Mr. Bailey has over thirty-one years in management roles at both medical device and pharmaceutical companies. From 1991 to 1995, Mr. Bailey was the leader of the sales organization of Pharmacia Ophthalmics, Inc. Mr. Bailey was the Vice President of Sales and Marketing for Novoste, Inc. (NASDAQ) a start up cardiovascular company from 1989 to 1991, where he initiated the entire sales and marketing organization.
Mr. Bailey was Co-founder and Vice President of Sales and Marketing for Chiron Vision, Inc., which was acquired by Bausch & Lomb in 1997. Chiron Vision, now Bausch & Lomb Surgical, is a leader in the manufacturing and sales of ophthalmic devices worldwide.
From 1980 to 1986 Mr. Bailey was the initial Vice President of Sales and Marketing for Allergan Medical Optics, Inc., a leader in the ophthalmic field. Mr. Bailey built the sales and marketing department for Allergan Medical Optics, Inc. from its beginning to a staff of 123 people.
Laurence Schreiber – COO and Corporate Secretary and Treasurer
Larry is a seasoned business veteran with nearly 30 years of solid administrative experience. Mr. Schreiber also served as Chief Executive Officer of Ponte Nossa Acquisition Corporation, the predecessor of Advanced Refractive Technologies, Inc.. Prior to joining the company in 2001, Mr. Schreiber founded Diversified International, a multi-level marketing system, and served as Chief Executive Officer of Learn America, a multimedia productions company.
Larry Hood – Chief Engineer
Mr. Hood is the Company’s Director in charge of research and development of Advanced Refractive’s ophthalmic water jet product. Mr. Hood has over 35 years experience in designing and bringing systems to market in areas such as data acquisition, telemetry, orthopedic surgical, ophthalmic surgical, diagnostics, lasers and power ultrasonics. Mr. Hood has worked for Cavitron/Coopervision/Alcon, Biomet and Plesseys in the past, and is an inventor in a number of fields, with more than 50 U.S. patents issued or pending.
Norman Schwartz – General Counsel
Mr. Schwartz has over 32 years experience in business and finance. He received a JD from the University of Arizona and LLM (Taxation) from New York University. Mr. Schwartz was formerly on the staff of the Chief Counsel of the Internal Revenue Service in Washington D.C. Mr. Schwartz has served as CFO and CEO and a member of the Board of Directors for a number of both public and private companies.
Scientific Advisors
Irving J. Bigio, Ph.D. - University of Michigan
Eugene G. Levin, Ph.D. - University of California, Irvine
Key Advisor
Richard Lindstrom, MD – Chief Medical Advisor
Dr. Lindstrom is in charge of assisting and advising the Company in connection with product development in the ophthalmic surgical arena, and was responsible for establishing the Company’s Ophthalmic Development Team. Dr. Lindstrom is a recognized leader in corneal, cataract, refractive and laser surgery. Dr. Lindstrom plays an active role in the teaching program at the Phillips Eye Institute and at the University of Minnesota Hospital. He also serves as an Associate Director of the Minnesota Lions Eye Bank. He holds 27 patents in ophthalmology in intraocular lens implant technology, corneal preservation, irrigation solutions, viscoelastic solutions, intracorneal lenses, and associated surgical instruments. Dr. Lindstrom serves on the editing board of a variety of medical journals, including Journal of Cataract and Refractive Surgery, Ophthalmic Surgery, European Journal of Implant and Refractive Surgery, Implants in Ophthalmology, Ocular Surgery News, Ophthalmology Times, and Journal Review of Ophthalmology. He is Chief Medical Advisor to Laser Vision Centers and Vision 21 Centers.
http://www.advancedrefractive.com/Management.htm
this Co is UNREAL !!their technology is used in LASIK surgery procedure !!!
low O.S ,will move very high
they must be doing serious Cash$$$$$
nice dd as usual! I don't feel like as big of a bagholder as before having bought in @ .0038.
the LASIK procedure : http://www.allaboutvision.com/visionsurgery/lasik.htm
this Co is making serious $$$$$$
ARFR 0.0017 HUGE find $$$$their technology is used in LASIK procedure!!!!!
Advanced Refractive Technologies, Inc., an ophthalmology development company, engages in the identification, development, and marketing of ophthalmic surgery products. The company, utilizing its waterjet technology, is developing two ophthalmic surgery products, Accupulse cataract emulsifier and Hydrokeratome corneal cutting device for use in the laser eye surgery and cataract surgery markets. Accupulse cataract emulsifier is an emulsification device designed for the removal of the cataractous human crystalline lens in the eye. HydroKeratome is a corneal cutting device for use in the LASIK procedure
they have FDA approval !!!
check it
http://www.medcompare.com/details/30718/HydroKeratome-Waterjet-System.html
ARFR .002s back up!
this is a HUGE co $$$ Waterjet Technology
Waterjet technology is an established method for precision cutting of materials in a variety of industrial applications. It uses the principle of pressurizing water to extremely high levels, and allowing the water to escape in a controlled manner through a very small opening, or orifice. Water jets use the high velocity beam of water exiting the orifice to cut various materials, including tile, wood, plastic, metal, and stone. In general, industrial applications of waterjet technology are used in place of a laser or other device when the "cut" needs to be quicker, cleaner, and with minimum distortion and temperature increase.
Accupulse® Cataract Emulsifier
The Accupulse Cataract Emulsifier is an emulsification device designed for the quick and safe removal of the cataractous human crystalline lens in the eye, a necessary procedure before installing a new intraocular lens ("IOL"). The device creates a pulsating stream of saline solution, and the impact from the pulsating fluid emulsifies the cataractous human lens and breaks the lens into small pieces. The Accupulse simultaneously aspirates the emulsified tissue and removes it from the interior of the eye.
The Accupulse requires minimal technical skill, as it functions like a hydraulic eraser or paint brush. No sculpting or lens elevation or rotation is necessary. The balanced irrigation/aspiration fluidics complements the embedded CPU controlled micro pulses. The foot switch initiates the mode activity selected by surgeon for the balanced and ergonomically shaped hand piece.
Based on the experience of our management team and consultants in the ophthalmic industry, we believe that the waterjet platform of the Accupulse will be easier to learn to use and will require less skill than that required by current ultrasound phaco emulsification devices. The Company also expects that Accupulse and its disposable package will be priced in the low range of current ultrasound devices, which will make it attractive in underdeveloped markets, and also attractive in the U.S. and other nations where cost containment is critical
http://www.advancedrefractive.com/Products.htm
there is a HUGE demand for that
ARFR IHUB momo will carry this to a penny!
Watch for 3-day run.
yes it is!
Bounce done gone~~~~~~
Huge Buying going on and no huge dump. going to have a huge run by days end
what was the news again?
(((((ARFR))))) up 300%
bounce big BOUNCE UP
wwwweeeeeeeeeeeeee
I thought I cornerd the market on that. lol
i will not buy or chase this stock....now watch it run up to multiple pennys lolol it always happens to me.
No hurt here...In and out in a flash.
whats going on here another pump? there gonna make you chase it so be carefull
AFRF compunds hugh NEWS!!!!LD22-4
www.icbs.ca/?q=node/71
insert-text-here
the still own ocular therapeutics- I think OT is involved with ICBT.pk- ICBS ltd I think together they are trying to move forward with their
Canadian Bio Med Systems: www.canadianbiomed.com
Canadian Bio Med Systems is an ophthalmology company that is engaged in the development of pharmaceutical agents for two of the most important disease states in that market; Glaucoma and Age related macular degeneration.
Canadian Bio Med Systems along with its partner Ocular Therapeutics owns the exclusive worldwide licensing rights to two patented or patent pending drugs in the field of ophthalmology. It is believed that these drugs have the potential to revolutionize the way Glaucoma and Age Related Macular Degeneration (AMD) are treated.
Age-Related Macular Degeneration (AMD) is the leading cause of blindness, worldwide, for people over 55 years of age. The incidence of AMD in persons aged 55 is 1% and increases to 15% for persons aged 80. This debilitating disease has proven to be difficult to treat and only a very few drugs have been developed which have positive effects.
The drug under development by Canadian Bio Med Systems , has a very different mode of action than the current therapeutic products. It can be used alone or in conjunction with these currently available products.
The product under development by CBMS, LD22-4 has the advantage of being a very small molecule meaning that fewer treatments will be needed compared to current therapies, This will help reduce the pain and frequency of injection to the patient and potentially the cost of the treatment.
could this one be ready for lift-off?
this will explode one day!!!
I hope we gap up and run again for today! A little bit of volume can send this thing several ticks, imagine a huge amount of volume! If that happens, we will go to da moon!
markat cap $300k was once over $60 mil back in 2002 2003-
i think the company still owns some medical devices- but the huge opportunity is if they could ever partner with anyone on the drug said-
AMD
Glaucoma
THey just need funding--------- maybe $$$$ soon- maybe
L2: NITE at 0.0015 (1x) then 1x at 0.003 1x at 0.009
This L2 is sooo thin! We neeed more volume! Blue skies ahead!
I'm thinking less than 250mil now! The last share count was from 2006 which as about a bit more than 250mil! I'm thinking it's much less now considering this thing moves on such little buys!
what is the float on this?
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
215
|
Created
|
07/29/05
|
Type
|
Free
|
Moderators |
Advanced Refractive Technologies | |
Who Are We Advanced Refractive Technologies is an ophthalmic developmental and marketing company, which is focusing upon the most important areas of need in ophthalmology. The Company is developing both medical devices as well as pharmaceutical agents to be used in important pathologies within the ophthalmology market. These areas include:
Advanced Refractive Technologies is now preparing to revolutionize the ophthalmic market.
|
|
A cutting edge ophthalmic company focused
upon the identification, development and marketing
of innovative ophthalmic applications.
Advanced Refractive Technologies is an ophthalmic developmental and marketing company, which is focusing upon the most important areas of need in ophthalmology.
The Company is developing both medical devices as well as pharmaceutical agents to be used in important pathologies within the ophthalmology market.
These areas include:
Cataract detection
Cataract surgery
Glaucoma therapy
Age-Related Macular degeneration
Advanced Refractive Technologies, Inc
1062 Calle Negocio
San Clemente, California 92673
P:949.940.1300 ext. 326
F:949.940.1301
EMAILS
Nschwartz@advancedrefractive.com Public Relations/General Counsel
Rbailey@advancedrefractive.com CEO
Lschreiber@advancedrefractive.com possible IR contact
August 8, 2006: 244,469,073
February 15, 2007: 251,229,339
Transfer Agent:
Phone: 775-322-0626
Fax: 775-322-5623
gayle@natco.org
Website: http://www.advancedrefractive.com
WALLSTREETREPORTER INTERVIEW
http://www.wallstreetreporter.com/profile.php?id=19869
Dated August 25, 2006
SEC Filings:
http://www.sec.gov/cgi-bin/srch-edgar?text=advanced+refractive&first=2005&last=2006
ARFR Press Releases:
http://tinyurl.com/3x5x35
10/16/06 San Clemente firm finds patents' perfect match
http://www.ocregister.com/ocregister/money/abox/article_1312032.php
09/13/06 Preclinical Studies Underway on Advanced Refractive Technologies Novel Glaucoma Treatment
08/22/06 UTEK and Advanced Refractive Technologies, Inc. Announce Renewal of Strategic Alliance
08/17/06 Advanced Refractive Achieves Early Milestone
08/11/06 UTEK Transfers a Worldwide License for a New Treatment of Glaucoma to Advanced Refractive Technologies
05/10/06 Advanced Refractive Technologies Licenses Innovative Cataract Detection Device
03/31/06 Advanced Refractive Technologies, Inc. Announces Restructuring of Debt
08/01/05 VisiJet, Inc. Debuts as Advanced Refractive Technologies
Symbol Change from VJET to ARFR
VJET PR Archive:
http://tinyurl.com/2kpgpo
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |